Skip to content

Xencor XNCR Accrued liabilities

Accrued liabilities at other companies

Amgen logo
AmgenAMGN
Summit Therapeutics logo
Summit TherapeuticsSMMT

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.09B+79.8%
Enterprise value$1.25B+58.6%
P/S11.2×+6.4×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's accrued liabilities?
Xencor (XNCR) reported accrued liabilities of -$707K in Q1 2026.
How has Xencor's accrued liabilities changed year-over-year?
Xencor's accrued liabilities increased by 77.6% year-over-year, from -$3.15M to -$707K.